- |||||||||| NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date, Adverse events: Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions (clinicaltrials.gov) - Sep 25, 2018 P=N/A, N=3000, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Mar 2018 --> Jan 2017 | Trial primary completion date: Mar 2018 --> Dec 2016
- |||||||||| Phase classification, Enrollment change, Trial primary completion date: Focal Therapy for Prostate Cancer Using HIFU (clinicaltrials.gov) - Apr 20, 2018
P=N/A, N=354, Recruiting, Phase classification: P4 --> P=N/A | N=224 --> 108 | Trial primary completion date: Jul 2018 --> Mar 2018 Phase classification: P2 --> P=N/A | N=272 --> 354 | Trial primary completion date: Jun 2014 --> Dec 2028
- |||||||||| Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (clinicaltrials.gov) - Mar 20, 2018
P4, N=19, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=284 --> 19 | Trial completion date: Oct 2018 --> Mar 2018 | Trial primary completion date: Sep 2018 --> Dec 2017
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment change, Trial termination: A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation (clinicaltrials.gov) - Sep 20, 2017 P2, N=59, Terminated, N=74 --> 59 | Recruiting --> Terminated; Strategic business decision was made to terminate the program. There were no safety concerns.
- |||||||||| Trial completion, Trial primary completion date: Outcomes of Delivery in Patients With Dyspareunia (clinicaltrials.gov) - Oct 10, 2016
P=N/A, N=173, Completed, Active, not recruiting --> Completed | N=80 --> 2 Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Sep 2016
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment change, Trial primary completion date: A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation (clinicaltrials.gov) - Oct 5, 2016 P2, N=74, Recruiting, Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Sep 2016 N=60 --> 74 | Trial primary completion date: Oct 2016 --> Oct 2017
- |||||||||| Trial primary completion date: Outcomes of Delivery in Patients With Dyspareunia (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=200, Recruiting, N=950 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2015 --> Mar 2017
- |||||||||| Biomarker, Enrollment closed, Enrollment change, Trial primary completion date: HEART-MEND: Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes (clinicaltrials.gov) - Nov 27, 2015
P=N/A, N=568, Active, not recruiting, Active, not recruiting --> Completed | N=300 --> 200 | Trial primary completion date: May 2013 --> Dec 2015 Recruiting --> Active, not recruiting | N=1143 --> 568 | Trial primary completion date: Jan 2015 --> May 2016
- |||||||||| sildenafil / Generic mfg., testosterone gel / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Testosterone for Penile Rehabilitation After Radical Prostatectomy (clinicaltrials.gov) - Jun 20, 2015 P0, N=3, Terminated, Not yet recruiting --> Completed | N=72 --> 42 N=24 --> 3 | Recruiting --> Terminated | Trial primary completion date: Nov 2012 --> Mar 2013; Lack of volunteers who would consent to participate and lack of funding
|